Search
  • Within this site
AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Back to search results

In Vivo Photoacoustic and Photothermal Nano-Theranostics of Biofilms

IP Title

In Vivo Photoacoustic and Photothermal Nano-Theranostics of Biofilms


Detailed Technology Description

Attacking Resistant Bacteria with Gold Nanoparticles For many years the medical profession has had a good weapon to use to kill bacterial infections – anti-biotics.  Yet due to the evolution of bacteria, various strains of bacteria have developed resistance to almost every known anti-biotic.  One of the more well-known strains of resistant bacteria is Multi-Resistant Staphlococcus Aureus, or MRSA, which is estimated to be carried by up to 50 million people worldwide.  The mortality rate for MRSA infections is about 20%.  The number of species of bacteria that are resistant to bacteria is growing, increasing the need for a new way to combat these bacteria in the body. One new and promising method is to use photo-acoustic nanoparticles, specifically, gold nanoparticles that are functionalized to target bacteria.  The gold nanoparticles are coated with material that has an affinity for the target bacteria so that the nanoparticles are attracted to the bacteria and stick to them. After the patient has been injected with the gold nanoparticles, a laser pulse is applied to the site of the infection, which causes the gold nanoparticles to vibrate rapidly, thus heating and destroying the bacteria. Because this method of killing the bacteria is not related to the chemistry of the bacteria, or its metabolism, the method is useful in cases where the bacteria form a film.  Antibiotics are not as effective against bacterial in films because of the low metabolism of these bacteria, and thus reduces their effectiveness. The new treatment of resistant bacterial infections is patent-pending and is available for license.  For more information, contact: Mark Swaney479-575-7243mswaney@uark.eduRef 17-24


Application Date

Jun 2, 2015


Country/Region

USA

For more information, please click Here
Business of IP Asia Forum
Desktop View